NCT02863991: Phase 1/2: Oral ONC201 in Relapsed/Refractory Multiple Myeloma
NCT02863991: Phase 1/2: Oral ONC201 in Relapsed/Refractory Multiple Myeloma
ONC201 is an orally bioavailable first-in-class small molecule with demonstrated antitumor activity in preclinical models of difficult-to-treat solid and liquid tumors without imparting significant toxicity. This is a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone to patients with relapsed/refractory multiple myeloma.
Sponsor
ClinicalTrials.gov Identifier: NCT02863991
Official Title: Oral ONC201 in Relapsed/Refractory Multiple Myeloma
First Posted: August 11, 2016
Click here for details on ClinicalTrials.gov
Akt/ERK Inhibitor ONC201 (Code C113792)
Akt/ERK Inhibitor ONC201
ONC-201
ONC201
TIC10
Drug: ONC201
Location
United States, New York
United States, Pennsylvania